2.17% -0.0334

Regulus Therapeutics Inc (RGLS)

Regulus Therapeutics Inc Aktie (RGLS) Neueste Nachrichten

Regulus Therapeutics Inc (RGLS)

Regulus Therapeutics Inc Aktie (RGLS) Neueste Nachrichten

Oppenheimer’s latest rating for RGLS stock - Knox Daily

RGLS stock rated an Outperform by Oppenheimer - Knox Daily

Gaining Ground: Regulus Therapeutics Inc (RGLS) Closes Lower at 1.46, Down -6.41 - The Dwinnex

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Regulus Therapeutics (NASDAQ:RGLS) Raised to Sell at StockNews.com - MarketBeat

Regulus Therapeutics Inc [RGLS] Director makes an insider purchase of 4,000 shares worth 7280.0. - Knox Daily

Regulus Therapeutics Inc (RGLS) rating initates by Oppenheimer - Knox Daily

How does Regulus Therapeutics Inc (RGLS) change from a tortoise to a hare? - SETE News

Regulus Therapeutics Inc (RGLS) stock analysis: A comprehensive overview - US Post News

Regulus Therapeutics Inc (RGLS)’s stock chart: A technical perspective - US Post News

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - StockTitan

The Attractiveness of Investing In Regulus Therapeutics Inc (RGLS) is Growing - Knox Daily

Market Recap: Regulus Therapeutics Inc (RGLS)’s Positive Momentum, Closing at 1.59 - The Dwinnex

A Guide To The Risks Of Investing In Regulus Therapeutics Inc (RGLS) - Knox Daily

Vanguard Group Inc. Has $2.13 Million Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat

Regulus Therapeutics Reports Second Quarter 2024 Financial Resul - GuruFocus.com

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - Longview News-Journal

Oppenheimer Reiterates “Outperform” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - Longview News-Journal

Oppenheimer Reiterates Outperform Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat

Analyzing Regulus Therapeutics Inc (RGLS) After Recent Trading Activity - Knox Daily

Regulus Therapeutics Inc. Forecasted to Earn Q2 2025 Earnings of ($0.20) Per Share (NASDAQ:RGLS) - Defense World

Regulus Therapeutics (NASDAQ:RGLS) Earns Buy Rating from HC Wainwright - Defense World

Regulus Therapeutics Inc. Forecasted to Post Q2 2025 Earnings of ($0.20) Per Share (NASDAQ:RGLS) - MarketBeat

HC Wainwright Reiterates "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat

RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q2 2024 - InvestorPlace

Regulus: Q2 Earnings Snapshot - San Antonio Express-News

Regulus: Q2 Earnings Snapshot - San Francisco Chronicle

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates - Nasdaq

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates - PR Newswire

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - StockTitan

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - PR Newswire

Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated at Oppenheimer - Defense World

Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated at Oppenheimer - MarketBeat

RGLS stock rated an Outperform by Leerink Partners - Knox Daily

Regulus Therapeutics Inc (RGLS) did well last session? - US Post News

Regulus Therapeutics director buys $7.3k in company stock - Investing.com India

Regulus Therapeutics director buys $7.3k in company stock By Investing.com - Investing.com Canada

Regulus Therapeutics director buys $7.3k in company stock - Investing.com

A new trading data show Regulus Therapeutics Inc (RGLS) is showing positive returns. - SETE News

Regulus Therapeutics Inc. (NASDAQ:RGLS) Sees Large Decline in Short Interest - MarketBeat

Regulus Therapeutics Inc (RGLS) presents a great opportunity, but the stock is slightly overvalued - US Post News

Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Target Price at $11.75 - MarketBeat

Regulus Therapeutics (NASDAQ:RGLS) Given “Buy” Rating at HC Wainwright - Defense World

Regulus Therapeutics' (RGLS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Regulus Therapeutics’ (RGLS) “Buy” Rating Reiterated at HC Wainwright - American Banking and Market News

CVI Holdings LLC Invests $4.05 Million in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat

Short Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Grows By 48.0% - MarketBeat

Stock Market Recap: Regulus Therapeutics Inc (RGLS) Concludes at 1.79, a 1.70 Surge/Decline - The Dwinnex

RGLS overperforms with a 1.70 increase in share price - US Post News

Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesJuly 09, 2024 - BioSpace

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - Quantisnow

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - PR Newswire

Regulus Therapeutics Inc (RGLS) Stock: A Year of Stock Market Dynamics - The InvestChronicle

Regulus Therapeutics Inc [RGLS] Records 50-Day SMA of $2.2131 – Knox Daily - Knox Daily

There is no doubt that Regulus Therapeutics Inc (RGLS) ticks all the boxes. - SETE News

Uncovering the Potential of Regulus Therapeutics Inc (RGLS) Stock - The InvestChronicle

Regulus Therapeutics Inc (RGLS) stock: A year of ups and downs – US Post News - US Post News

Ähnlich wie RGLS